Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting
Evolus to present final results from Phase 2 study at 2023 ASDS Annual Meeting
Positive
Evolus to present final results from Phase 2 study on 40U PrabotulinumtoxinA-xvfs at ASDS Annual Meeting
Study evaluates safety, efficacy, and duration of effect in Glabellar Lines
Presentation by Sue Ellen Cox M.D.
Independent medical education session
10/25/2023 - 08:45 AM
Oral abstract will be presented on Friday, November 3, 2023
NEWPORT BEACH, Calif. --(BUSINESS WIRE)--
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sue Ellen Cox M.D. will present final results from the Phase 2 study evaluating the safety, efficacy and duration of effect of 40U PrabotulinumtoxinA-xvfs at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting on November 3, 2023, in Chicago during an independent medical education session.
Oral Presentation Information
Title : A Phase II, Randomized, Double Blind, Active-Controlled, Increasing Dose Trial to Study the Safety and Duration of Effect of 40U PrabotulinumtoxinA-xvfs in Glabellar Lines: Final Results
Time : 4:30 to 5:30 pm CT, Friday, November 3, 2023
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the brand name Nuceiva®. The product is manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, a line of five unique dermal fillers currently in late-stage development. Visit us at www.evolus.com , and follow us on LinkedIn , Twitter , Instagram or Facebook .
Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231024386212/en/
Investor Contact:
Idalia Rodriguez, Ned Mitchell
Arbor Advisory Group
Email: ir@evolus.com
Media Contact:
Email: media@evolus.com
Source: Evolus
What is the focus of Evolus, Inc.?
Evolus is a performance beauty company with a focus on building an aesthetic portfolio of consumer brands.
What will be presented at the 2023 ASDS Annual Meeting?
Final results from the Phase 2 study on 40U PrabotulinumtoxinA-xvfs in Glabellar Lines.
Who will be presenting the results?
When and where will the presentation take place?
The presentation will take place on November 3, 2023, at the ASDS Annual Meeting in Chicago during an independent medical education session.
What does the study evaluate?
The study evaluates the safety, efficacy, and duration of effect of 40U PrabotulinumtoxinA-xvfs in Glabellar Lines.
EOLS Rankings
#2678 Ranked by Stock Gains
EOLS Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
Country
US
City
Newport Beach
About EOLS
evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.